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Abstract
Objective: Comorbid NAFLD is increasingly being diagnosed in patients with diabe‐
tes and nondiabetic endocrinopathies. The aim of this study was to assess hepatic 
steatosis noninvasively by transient elastography in patients with acromegaly.
Design: A cross‐sectional study including 22 patients with acromegaly.
Methods: Hepatic steatosis was quantified using controlled attenuation parameter 
(CAP) during elastography. Anthropometric measurements were obtained, serum 
liver function tests and lipid and hormone profiles were measured, and prosteato‐
genic gene variants were genotyped using standard assays.
Results: In	total,	41%	of	patients	were	women	(mean	age	60	±	14.7	years,	mean	BMI	
31.2	±	4.6	kg/m2).	Hepatic	steatosis,	as	defined	by	CAP	>	248	dB/m,	was	present	in	
66%	of	patients.	 Five	 (45%)	of	 the	patients	with	hepatic	 steatosis	 also	had	 fibrosis,	
and one presented with cirrhosis. Nine patients were carriers of the PNPLA3	p.I148M	
prosteatogenic [M] risk allele, eight of whom were heterozygotes. CAP values were sig‐
nificantly (P	=	.045)	higher	in	these	patients	and	corresponded	to	advanced	steatosis,	
as compared to patients with the wild‐type genotype, who demonstrated CAP values 
consistent	with	mild	steatosis	(311	±	33	dB/m.	vs	254	±	62	dB/m).	CAP	values	did	not	
differ significantly in carriers of distinct TM6SF2 and MBOAT7 genotypes; however, 
carriers of the risk alleles displayed higher CAP as compared to wild‐type patients.
Conclusions: This study shows that in patients with acromegaly, carriers of the PNPLA3 
susceptibility allele are at risk of developing hepatic steatosis, as assessed by CAP. 
Comorbid NAFLD might compound prognosis in such patients; thus, further research 
into the pathomechanisms and treatment of NAFLD in acromegaly is warranted.
K E Y W O R D S
adiponutrin, controlled attenuation parameter, MBOAT7, nonalcoholic fatty liver disease, 
TM6SF2, transient elastography
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1  | INTRODUC TION
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of 
liver conditions, ranging from bland steatosis to nonalcoholic ste‐
atohepatitis (NASH), which results in progressive hepatic fibrosis. 
Patients with NAFLD are at risk of liver cirrhosis and hepatocellular 
carcinoma.1 The pathogenesis of NAFLD is still not entirely under‐
stood. The risk is increased by environmental risk factors such as 
metabolic‐related challenges but also in the presence of genetic vari‐
ations.2	For	instance,	the	mutation	p.I148M	in	the	gene	encoding	the	
triglyceride hydrolase patatin‐like phospholipase domain–containing 
3 (PNPLA3)	rs738409	(also	referred	to	as	adiponutrin)	is	reported	to	
be a major risk factor for NAFLD.2 In addition, common genetic vari‐
ations in the membrane‐bound O‐acyltransferase domain–contain‐
ing 7 (MBOAT7) and in the transmembrane 6 superfamily member 2 
(TM6SF2) genes have also been associated with increased suscepti‐
bility to NAFLD and its severity.3
Comorbid NAFLD is becoming progressively more prevalent in 
certain conditions such as the metabolic syndrome, which is a well‐
established risk factor.4	NAFLD	has	also	been	reported	in	up	to	80%	
of patients with type 2 diabetes.5 Nondiabetic endocrinopathies are 
also increasingly being linked to fatty liver.6,7 Hypothyroidism has 
been associated with NAFLD,6 as have patients with increased cir‐
culation	of	androgens,	evidenced	by	occurrence	rates	of	up	to	70%	
in women with polycystic ovarian syndrome (PCOS).8
Acromegaly is another endocrinopathy of interest, which is 
characterized by the hypersecretion of growth hormone (GH). GH 
triggers hepatic and systemic insulin‐like growth factor 1 (IGF‐1) 
production.9 Both GH and IGF‐1 are suggested to play an import‐
ant role in the metabolism of hepatic fat.10 Treatment‐naïve patients 
with acromegaly are reported to commonly have elevated serum tri‐
glyceride concentrations in addition to insulin resistance and visceral 
adipose tissue accumulation—factors associated with NAFLD.11 
Furthermore, certain treatments for acromegaly can compound this 
clinical picture, as they have been associated with altered hepatic fat 
accumulation and liver dysfunction.12-14 This has been illustrated in 
a randomized study that reported increased accumulation of hepatic 
fat after cotreatment of somatostatin analogue with the GH recep‐
tor antagonist, pegvisomant.14
Overall, there has been a little attention on the role of NAFLD 
in patients with acromegaly; thus, the objective of this cross‐sec‐
tional study was to investigate the associations between the clinical 
features of acromegaly and NAFLD, taking into account the genetic 
make‐up of the individual patients.
2  | PATIENTS AND METHODS
This study recruited adult patients diagnosed with acromegaly from 
within the Department of Medicine II at Saarland University Medical 
Center, who were willing to provide informed consent for partici‐
pation. The diagnosis of acromegaly was based on IGF‐1 concen‐
trations in blood and the absence of growth hormone suppression 
during an oral glucose tolerance test (OGTT). Patients were ex‐
cluded if they presented with chronic hepatitis B or C virus infec‐
tion; had significant long‐term alcohol consumption that surpassed 
21	and	14	standard	alcoholic	drinks	per	week	for	men	and	women,	
respectively15; were taking steatogenic medications; or presented 
with monogenic hereditary liver diseases.15 The study was approved 
by the Ärztekammer des Saarlandes local ethical committee (Refs. 
#271/11 and #67/16) and conducted within the framework of the 
Declaration of Helsinki.
2.1 | Anthropometric, clinical and biochemical 
assessments
Height and weight were recorded together with transient elas‐
tography using a stadiometer and a scale (seca 217 and seca 
701, respectively; Seca), from which body mass index (BMI) was 
calculated. Waist circumference (WC) was obtained, and a full 
medical history was taken, which included previous and current 
medications. Fasted blood samples were collected for routine 
analyses including liver function tests, serum lipids and relevant 
hormones. Specifically, the following parameters were quanti‐
fied: surrogate markers for liver function, including alanine ami‐
notransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (AP) and γ‐glutamyl transpeptidase (γ‐GT); the fol‐
lowing lipid status markers: triglycerides (TGs), total cholesterol 
(TC), high‐density lipoprotein (HDL) cholesterol and low‐density 
lipoprotein (LDL) cholesterol; and glucose‐related markers and 
hormones: HbA1c, total testosterone, free testosterone, follicle‐
stimulating hormone (FSH), luteinizing hormone (LH), oestradiol, 
sex hormone‐binding globulin (SHBG), cortisol, adrenocortico‐
trophic hormone (ACTH), somatotrophic hormone (STH), insulin‐
like growth factor 1 (IGF‐1; concentration and standard deviation 
(SD) score) and prolactin.
2.2 | Noninvasive assessment of hepatic 
steatosis and fibrosis
Hepatic steatosis and liver stiffness were simultaneously quantified 
using the noninvasive vibration‐controlled transient elastography 
(VCTE; FibroScan®, Echosens), which yields liver stiffness measure‐
ments (LSMs) ranging from 1.5 to 75.0 kPa and controlled attenua‐
tion	parameter	 (CAP)	values	between	100	and	400	dB/m.	The	full	
technique has been described previously.16 CAP results were only 
included if they were based on 10 valid measurements. Furthermore, 
if	the	success	rate	surpassed	60%	and	the	interquartile	range	(IQR)	
for	LSM	was	≤30%,	then	LSM	results	were	also	included,	as	per	the	
EASL‐ALEH Clinical Practice Guidelines.17 For LSM values <7.1 kPa, 
the IQR/LSM ratio was not a criterion for inclusion.18
2.3 | Genotyping of risk variants
For genotyping, we followed the membrane‐based QIAamp pro‐
tocol (Hilden, Germany) for the DNA isolation from EDTA blood. 










The software programs spss 20.0 (SPSS) and Graphpad prism	 7.04	
(GraphPad Software) were used for all statistical analyses. Results 
based	on	continuous	data	are	presented	as	mean	±	SD	or	median	
(range), based on the data distribution. According to a recent meta‐
analysis	of	individual	participant	data,	the	CAP	cut-off	248	dB/m	is	
used to differentiate steatosis from no steatosis, corresponding to 
the	histological	S0	and	≥S1	categories.19 Therefore, we carried out 
subgroup analysis using this cut‐off. Furthermore, we interpreted 
LSM > 6.0 kPa to indicate the presence of fibrosis, where we cat‐
egorized values between 6 and 12 kPa as manifest liver fibrosis and 
values >12.0 kPa as liver cirrhosis.17 Based on the data distribution, 
either the t test or Mann‐Whitney U test was used to assess for sig‐
nificance between two unpaired groups and ANOVA or the Kruskal‐
Wallis test was used for comparing three such groups. Categorical 
variables were evaluated using contingency tables. Univariate re‐
gression analysis was planned a priori for the two variables BMI and 
PNPLA3 genotype to assess for associations with hepatic steatosis 




A total of 22 patients with acromegaly who were treated at our 
centre were included in this cross‐sectional analysis. Table 1 sum‐
marizes their characteristics. The mean age of the patients was 
60.0	±	14.7	years,	and	nine	patients	(41%)	were	women.	One	pa‐
tient had a BMI in the normal range (<25 kg/m2), eight patients 
were overweight (BMI 25.0‐29.9 kg/m2), and the remaining 13 
patients	were	categorized	as	obese	 (BMI	≥	30	kg/m2). Waist cir‐
cumference values were within the normal range for five men, and 
the remaining men and women were above the normal thresholds 
(<94	cm	for	men;	<80	cm	for	women).	Approximately	one-third	of	
the cohort had a diagnosis of diabetes type 2, and two‐thirds pre‐
sented with arterial hypertension.
3.1.1 | Liver profiles
Figure 1A summarizes the CAP and LSM results of the noninva‐
sive	 transient	 elastography.	 Using	 the	 CAP	 cut-off	 248	 dB/m	 to	
determine the presence of hepatic steatosis, 11 patients were diag‐
nosed with fatty liver. Of these, five patients also had manifest liver 
fibrosis (LSM between 6 and 12 kPa), and one patient presented with 
liver cirrhosis (>12 kPa). Figure 1B demonstrates that the median 


































Total cholesterol (mg/dL) 215	±	45
LDL cholesterol (mg/dL) 124	±	45
HDL cholesterol (mg/dL) 52	(23-147)
Abbreviations: ACTH, adrenocorticotrophic hormone; ALT, alanine 
aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotrans‐
ferase; BMI, body mass index; CAP, controlled attenuation parameter; 
FSH, follicle‐stimulating hormone; HDL, high‐density lipoprotein; IGF‐1, 
insulin‐like growth factor 1; LDL, low‐density lipoprotein; LH, luteiniz‐
ing hormone; LSM, liver stiffness measurement; SD, standard deviation; 
SHBG, sex hormone‐binding globulin; STH, somatotrophic hormone; 
WC, waist circumference; γ‐GT, gamma‐glutamyl transpeptidase.
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CAP values increase with advancing liver disease. In terms of liver 
function tests, one patient had elevated ALT, AST and AP activities, 
and three patients had increased AST levels only; finally, raised γ‐GT 
activities were documented in six patients.
3.1.2 | Lipid profiles
Overall,	 68.2%	 of	 the	 patients	 displayed	 elevated	 serum	 TG	
(>150	 mg/dL)	 and	 63.6%	 raised	 TC	 concentrations	 (>200	 mg/dL).	
LDL cholesterol was above the normal threshold of 120 mg/dL in 
40.9%,	and	9.0%	of	the	patients	had	HDL	cholesterol	values	<40	mg/
dL. HbA1c was above the normal range in six patients (all of which 
had a diagnosis of diabetes). Incidentally, not all the diabetic patients 




centrations between patients, only three patients demonstrated 
elevated values. Prolactin concentrations were within the normal 
range for six patients and were elevated in one patient, whilst 15 
patients had values below normal. Both STH and SHBG concentra‐
tions were raised in two and four patients, respectively, and three 
patients had SHBG levels below the normal threshold. Only one 
patient had elevated ACTH concentrations. Two patients displayed 
total testosterone levels above the threshold, four were below, and 
10 patients were in the normal range (there were missing values for 
six patients).
The majority of patients had FSH values within the normal range 
(n = 16), and one and four patients had values above and below this 
range, respectively. Likewise, 13 patients had normal LH concentra‐
tions and seven displayed elevated values (cut‐off could not be de‐
termined for two patients). Finally, six patients had normal oestradiol 
levels, whereas this was below the normal threshold for one patient 
(the cut‐off could not be determined for 15 patients).
3.1.4 | Medications
The patient sample was documented as taking the following medica‐
tions: seven patients were receiving octreotide only, four were on 
octreotide and cabergoline cotreatment, and one patient received 
octreotide together with pegvisomant. Two patients were taking 
pegvisomant alone, and one was receiving pegvisomant with caber‐
goline. Seven patients were untreated.
3.1.5 | Genotyping results
Genotyping results were available for 21 of the 22 patients and are 
summarized in Table 2. Nine patients were carriers of the PNPLA3 
p.I148M	risk	allele,	of	whom	only	one	was	homozygous	 (MM)	and	
eight were heterozygous (IM). The remaining 12 patients did not 
carry the risk allele (wild type [II]). For the TM6SF2 gene, six patients 
were heterozygous (EK) and 15 did not carry the risk allele (EE). 
Three patients were homozygous (EE) for the MBOAT7 risk allele, 
with 11 patients being heterozygous (GE) carriers, and seven carried 
the wild‐type genotype (GG).
3.2 | Hepatic steatosis is influenced by risk 
genotypes in patients with acromegaly
CAP	values	were	available	for	18	of	the	21	patients	who	were	geno‐
typed. From these, 17 were included based on fulfilling our criteria 
for CAP inclusion. Heterozygous carriers of the prosteatogenic (M) 
PNPLA3 risk allele had significantly (P	=	 .045)	higher	CAP	as	com‐
pared to the wild‐type group (Figure 2). A comparison of CAP values 
based on MBOAT7 and TM6SF2 genotypes revealed no significant 
differences between wild‐type, heterozygous and homozygous 
groups and the wild‐type and heterozygous groups, respectively. 
Nevertheless, mean CAP values were lower in carriers of the wild‐
type genotype than in heterozygous patients for both genotypes, as 
illustrated in Figure 2. Additionally, the MBOAT7 genotype included 
patients homozygous for the risk allele, in whom the mean CAP 
value was highest.
F I G U R E  1   A, Boxplots depicting noninvasive transient 
elastography results for controlled attenuation parameter (CAP) 
and liver stiffness measurements (LSMs) in the entire study group. 
B, Boxplots comparing CAP values for the four different groups of 
patients with acromegaly: patients without fatty liver compared to 
patients with fatty liver, and with fibrosis and cirrhosis. The CAP 
cut-off	for	fatty	liver	was	248	dB/m.	Liver	fibrosis	was	defined	by	
LSM > 6.0 kPa, and LSM > 12.0 kPa indicated cirrhosis
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3.3 | PNPLA3 p.I148M risk allele is associated with 
higher CAP
Table 3 summarizes the patient characteristics based on the pres‐
ence or absence of the PNPLA3	p.I148M	risk	allele	(M)	(of	note,	
comparisons with the homozygous group have been omitted due 
to only one patient being present in that category). The seven 
patients with one prosteatogenic (M) risk allele who had valid 
CAP values were all above the threshold for diagnosing hepatic 
steatosis	 (CAP>	 248	 dB/m).	 This	 contrasted	with	 only	 four	 out	
of the nine patients in the wild‐type group. Moreover, three of 
these patients in the risk group had liver fibrosis and one was 
categorized as having cirrhosis, as per the valid transient elastog‐
raphy results.
Concentrations of IGF‐1 also differed significantly (P = .031) be‐
tween groups, with the PNPLA3 risk allele carriers displaying lower 
values	112	(50-377)	ng/mL	vs	171	(82-292)	ng/mL.	Though	the	re‐
maining comparisons were not significantly different, Table 3 further 
illustrates that acromegaly patients with the PNPLA3 risk allele pre‐
sented with markedly higher BMI and WC. Additionally, LFTs were 
higher in these patients, who also had lower median HbA1c when 
compared to the wild‐type group.
3.4 | Clinical phenotypes do not differ based on the 
presence of hepatic steatosis
A subgroup comparison was carried out based on the presence or 
absence	of	hepatic	steatosis,	as	defined	by	CAP	cut-off	248	dB/m.	
This corresponded to 12 vs 6 patients; however, when comparing 
the clinical characteristics between these two groups, no significant 
differences were observed.
A further analysis comparing CAP scores in patients receiving 
pegvisomant with those not on medications or with those receiving 
somatostatin analogues or cabergoline revealed no differences.
3.5 | Univariate regression analysis reveals 
associations with CAP
Linear univariate regression analysis for CAP values as continuous 
variable was carried out for two variables (PNPLA3 genotype and 
BMI), agreed on a priori; however, no significant associations were 
observed.
4  | DISCUSSION
This cross‐sectional study evaluated the clinical features of patients 
with acromegaly and assessed for hepatic steatosis as well as for 
genetic determinants related to NAFLD. Hepatic steatosis was pre‐
sent	in	66%	of	the	patients	when	using	a	CAP	cut-off	of	248	dB/m,	
this finding is similar to another recent study that reported hepatic 
steatosis	in	61%	of	acromegaly	patients	using	the	hepatic	steatosis	
index.20 Furthermore, five of the included patients with hepatic ste‐
atosis also had fibrosis and one had cirrhosis. Moreover, the PNPLA3 
risk	allele	was	highly	prevalent	 in	 this	 small	 sample	 (in	41%	of	 the	
patients). Indeed, all patients who carried one PNPLA3	 p.I148M	
prosteatogenic [M] risk allele had CAP values above the suggested 
TA B L E  2   Number of patients based on genotype
 
Number of patients per genotype
Wild‐type Heterozygote Homozygote
PNPLA3	p.I148M 12 8 1
TM6SF2 p.E167K 15 6 0
MBOAT7 p.G17E 7 11 3
Abbreviations: MBOAT7, membrane‐bound O‐acyltransferase domain–
containing 7; PNPLA3, patatin‐like phospholipase domain–containing 3; 
TM6SF2, transmembrane 6 superfamily member 2.
F I G U R E  2   Individual	patient	CAP	scores	(as	well	as	mean	±	SD)	based	on	genotype	for	the	following	single	nucleotide	polymorphisms:	
patatin‐like phospholipase domain–containing 3 (PNPLA3)	p.I48M;	membrane-bound	O-acyltransferase	domain–containing	7	(MBOAT7) 
p.G17E; and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K. CAP values differed significantly (P	=	.045)	between	patients	
who were heterozygous carriers of the PNPLA3 risk allele (IM) as compared to the wild‐type patients (II). No significant differences in CAP 
were demonstrated between the three MBOAT7 genotypes, where the lowest mean CAP value was observed in carriers of the wild‐type 
genotype (GG) and the highest in patients homozygous for the risk allele (EE). No difference in CAP was observed between the TM6SF2 
genotypes
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threshold	 for	 hepatic	 steatosis	 (>248	 dB/m).	 Moreover,	 the	 mean	
CAP value for these patients corresponded to advanced steatosis 
(S3) and was significantly higher (P	=	 .045)	when	compared	to	the	
mean CAP value of the wild‐type patients who did not possess the 
risk allele, which corresponded to mild steatosis, S1.19
How acromegaly is associated with increased risk of hepatic 
steatosis is not entirely understood, but might be mediated by the 
presence of obesity. Moreover, we previously reported significantly 
higher CAP values in carriers of the PNPLA3 risk allele in patients 
with chronic liver diseases.16 Moreover, metabolic and endocrine 
factors may interact and have dynamic effects on hepatic steatosis 
in acromegaly. Specifically, growth hormone (GH) stimulates insulin 
resistance via its induction of gluconeogenesis and glycogenolysis, 
and indeed, hepatic lipid accumulation has been associated not only 
with GH deficiency but also with GH excess.20 Detrimental conse‐
quences on glucose metabolism, insulin signalling and adipose tissue 
have been documented in patients with acromegaly and GH excess. 
For instance, insulin resistance is associated with increased lipolysis 
and elevated circulating free fatty acids are seen in acromegaly pa‐
tients.21 On the contrary, deficiencies of both GH and IGF‐1 have 
been associated with an increased risk of NAFLD, as shown in animal 
models with GH deficiency, in whom hepatic steatosis is reversed 
upon correction of GH and IGF‐1 concentrations.22 Indeed, lower 
GH concentrations have been reported in human studies with partic‐
ipants diagnosed with NAFLD.23,24 Moreover, low serum IGF‐1 con‐
centrations have also been associated with NAFLD and it has been 
suggested that hepatic insulin resistance modulates hepatic GH pro‐
duction and thus IGF‐1 concentrations.25,26 A recent study showed 
hepatic steatosis (as assessed by a surrogate marker, the hepatic ste‐
atosis index) to be related to insulin resistance and the reduction of 
IGF‐1 and GH levels; after 12 months of follow‐up, improvements to 
insulin sensitivity paralleled reductions of hepatic steatosis.20
The observed risk with GH and IGF‐1 deficiencies would imply 
that treated patients with acromegaly might be prone to develop 
NAFLD, because treatment does, in some cases, lead to the devel‐
opment of GH deficiency, as illustrated in a recently published case 
study.27 Moreover, an intervention study and another case study 
both report histological NASH resolution upon GH correction in 
patients with GH deficiency.28,29 None of the patients herein had 
a deficiency in IGF‐1 concentrations; therefore, other mechanisms 
must exist through which NAFLD risk is amplified.
The GH receptor antagonist, pegvisomant, has also been associ‐
ated with intrahepatic lipid accumulation. In a randomized prospective 
study by Madsen et al.14, cotreatment of somatostatin analogue with 
pegvisomant in 12 patients resulted in increased intrahepatic lipid 
concentrations, as quantified using proton magnetic resonance spec‐
troscopy (1H MRS). Moreover, the authors found the weekly dose of 
pegvisomant correlated positively with accumulation of intrahepatic 
fat and speculated that the intermittent elevations in liver enzymes 
might be partially responsible for this effect. A subgroup analysis of our 
sample of patients with acromegaly did not reveal any significant dif‐
ferences in CAP values based on the medications taken. However, as 
described in Results section, there was a significant overlap between 
TA B L E  3   Patient characteristics based on PNPLA3	p.I148M	risk	
genotype
 
Patients with one 
PNPLA3 risk allele
Patients with no 
PNPLA3 risk allele
Sociodemographic characteristics
N (men/women) 8	(3/5) 12	(8/4)




Body weight (kg) 95.2	±	22.2 88.6	±	12.4
BMI (kg/m2) 31.3	±	4.8 30.1	±	3.9





Oestradiol (pg/mL) 16	(5	-	44) 5 (0 ‐ 10)
FSH (mIU/mL) 5.0 (1.0 ‐ 50.2) 4.7	(0.4	-	56.8)
LH (mIU/mL) 2.5 (0.1 ‐ 21.0) 2.6	(0.1	-	28.1)
Prolactin (µiu/mL) 67 (5 ‐ 196) 68	(4	-	379)
SHBG (mmol/L) 47	(20	-	55) 41	(11	-	107)
Cortisol (µg/dL) 10.2	(6.3	-	41.1) 9.9 (1.7 ‐ 26.6)
ACTH (pg/mL) 9.0	±	4.2 14.5	±	8.4
STH (ng/mL) 1.5 (0.1 ‐ 29.0) 0.9 (0.1 ‐ 12.6)
IGF‐1 (ng/mL) 112 (50 ‐ 377)*  171	(82	-	292)§
Liver markers
CAP (dB/m) 311	±	33**  254	±	62** 
LSM (kPa) 5.3	(3.8-15.8) 5.4	(3.5-10.3)
ALT (U/L) 29	(18-59) 23 (10‐96)
AST (U/L) 27	(22-34) 23 (17‐67)
AP (U/L) 74	(61-97) 72	(45-251)















Abbreviations: ACTH, adrenocorticotrophic hormone; ALT, alanine 
aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotrans‐
ferase; BMI, body mass index; CAP, controlled attenuation parameter; 
FSH, follicle‐stimulating hormone; HDL, high‐density lipoprotein; 
IGF‐1, insulin‐like growth factor 1; LDL, low‐density lipoprotein; LH, 
luteinizing hormone; LSM, liver stiffness measurement; SHBG, sex 
hormone‐binding globulin; STH, somatotrophic hormone; WC, waist 
circumference; γ‐GT, gamma‐glutamyl transpeptidase.
*P = .030. 
**P	=	.045.	
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several medications (eg, pegvisomant, somatostatins and cabergoline), 
which might have obviated any associations. We found elevations in 
liver enzymes to occur in a small number of patients only, despite high 
occurrence of hepatic steatosis. This finding reinforces that hepatic 
steatosis can occur in the absence of elevated LFTs. Moreover, when 
comparing the general characteristics of patients with versus without 
hepatic	steatosis	(based	on	CAP	cut-off	248	dB/m),	we	could	not	find	
any significant differences between the two groups.
The current study is limited by the small sample size and the chance 
of false‐positive findings. Moreover, being a cross‐sectional design, the 
longer‐term hepatic and extrahepatic implications could not be eval‐
uated. Studies with larger patient samples are needed to confirm the 
findings reported herein. Moreover, a comparison of the prognosis for 
acromegaly patients with NAFLD versus patients without NAFLD is 
needed. It is known that acromegaly is associated with acromegalic car‐
diomyopathy30 and that NAFLD is an independent risk factor for cardio‐
vascular disease.31 Therefore, it would be beneficial to screen patients 
with acromegaly for the presence of NAFLD and manage accordingly. 
This is important because hepatic steatosis can be effectively mediated 
via lifestyle interventions, as recommended in the official guidelines.15
The significant genetic associations reported herein also war‐
rant further investigation due to the small sample size included. We 
demonstrated that the PNPLA3 gene was significantly associated 
with higher CAP values in carriers of the risk allele. The PNPLA3 
gene is a strong risk factor, not only for developing hepatic ste‐
atosis but also for NASH, fibrosis and cirrhosis.32 Moreover, the 
PNPLA3 gene has been associated with increased risk of cardio‐
vascular disease in the setting of type II diabetes.33 Thus, lifestyle 
interventions for patients with the inherently increased risk of a 
poorer prognosis would be advantageous. Interestingly, we and 
others have shown that lifestyle interventions appear to be more 
effective in carriers of the PNPLA3 risk allele when compared to 
noncarriers, as evidenced in several studies.34,35 We did not find 
differences in CAP values based on the TM6SF2 and MBOAT7 geno‐
types; however, a trend for higher CAP was observed based on the 
presence of risk alleles. This finding is in line with recent research 
supporting a stronger role of PNPLA3 as compared to TM6SF2 and 
MBOAT7 genotypes in terms of severity of hepatic‐related injury.36
5  | CONCLUSION
Patients with both acromegaly and PNPLA3 genetic risk present with 
a greater degree of hepatic steatosis as compared to patients with 
acromegaly without this genetic risk. This association should be in‐
vestigated in larger patient cohorts. Since comorbid NAFLD might 
compound prognosis in such patients, further research into the role 
of NAFLD in acromegaly is warranted. 
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